Gyre Therapeutics, a biotechnology firm focusing on chronic organ diseases, announced today that the National Medical Products Administration of China has approved Gyre Pharmaceuticals’ avatrombopag maleate tablets.

Senti Biosciences, Inc. announced today that it has received an $8 million grant from the California Institute for Regenerative Medicine to advance its Phase 1 clinical trial of SENTI-202. This innovative therapy,

Sandoz has received FDA approval for Pyzchiva®, a biosimilar developed by Samsung Bioepis Co., Ltd. The approval includes formulations for subcutaneous injection and intravenous infusion

Soleno Therapeutics, Inc. has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of DCCR extended-release tablets.

KBio has announced that the FDA has cleared its investigational new drug application for EV68-228-N, a human monoclonal IgG1 antibody targeting enterovirus D68 capsid. This antibody is intended for intravenous treatment of acute flaccid myelitis

Arch Biopartners Inc. has announced a significant advancement in its development of cilastatin, a drug candidate designed to prevent acute kidney injury

Concerto Biosciences, based in Cambridge, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin Phase 1 trials of Ensemble No.2

TRex Bio, Inc., a biotechnology company focused on deciphering human tissue immune biology to create innovative therapeutics, has announced a significant milestone. Its partner, Eli Lilly and Company, has initiated a Phase 1 first-in-human study of TRB-051

Roche has received approval from the European Commission for OCREVUS® (ocrelizumab) subcutaneous (SC) formulation, expanding its use to treat both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis

Exsilio Therapeutics, a biotechnology company focused on developing genomic medicines for a wide range of diseases, has announced its emergence from stealth mode after securing $82 million in Series A financing